Prostate Cancer

An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.

Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.

Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.

The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.

Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.

Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.

An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.

Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Tanya Dorff, MD, reviews the available treatment options for nonmetastatic castration-resistant prostate cancer to select a treatment for 57-year-old patient.

Naomi Haas, MD, discusses the current areas of ongoing research in the treatment landscape for patients with prostate cancer.

During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.

The FDA has updated the Prescribing Information for the approved agent darolutamide to include improvement in overall survival in patients with non-metastatic castration-resistant prostate cancer, as well as other secondary end point data, from the phase 3 ARAMIS clinical trial.

Prostate-specific membrane antigen–targeting diagnostic agents are moving forward toward greater clinical use in PET imaging for prostate cancer.

Maha Hussain, MD, discusses the current role of PARP inhibitors in the treatment landscape of prostate cancers and where she sees this therapeutic approach evolving in the coming years.

During a debate at the 27th Annual Prostate Cancer Foundation Virtual Scientific Retreat, Daniel Spratt, MD, debated Daniel Lin, MD, on the subject of genomic classifiers in prostate cancer.

Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.

During a Targeted Oncology Case Based Peer Perspective event, Mayer N. Fishman, MD, PhD, discussed the case of a 60-year-old man with progressing prostate cancer.

Experts in genitourinary oncology share their excitement for promising emerging agents and combination therapies for advanced prostate cancer in the coming years.

Mary-Ellen Taplin, MD, presents data from the phase 2 TRITON2 trial of rucaparib in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, presents data from the phase 3 PROfound trial of olaparib in metastatic castration-resistant prostate cancer.

Patrick G. Pilié, MD, presents data from the phase 3 CARD trial of cabazitaxel in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, shares her method for selecting and dosing chemotherapy for metastatic castration-resistant prostate cancer.

Experts in genitourinary oncology review the treatment choices available after metastatic castration-resistant prostate cancer progression on abiraterone acetate + prednisone.

Jorge A. Garcia, MD, FA, describes the case of a 72-year-old man with metastatic castration-resistant prostate cancer.

Patrick G. Pilié, MD, presents data from the phase 3 PROSPER trial of enzalutamide, and Ganesh V Raj, MD, PhD, presents data from the phase 3 ARAMIS trial of darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Ganesh V Raj, MD, PhD, presents data from the phase 3 SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Experts in genitourinary oncology discuss how they choose therapy for patients with long PSA doubling times in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Experts in genitourinary oncology share how they decide between the 3 antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: apalutamide, enzalutamide, and darolutamide.

Experts in genitourinary oncology share their methods and patient specific factors that aid in selecting therapy for nonmetastatic castration-resistant prostate cancer.

Ganesh V Raj, MD, PhD, and Mary-Ellen Taplin, MD, review the role of next-generation sequencing in nonmetastatic castration-resistant prostate cancer, and who qualifies based on NCCN guidelines.